Since its inception in early 2014, the SAG initiative has exercised considerable impact on the clinical research landscape by inciting important dialogue between site professionals and industry leaders related to current and evolving practices.
The Society for Clinical Research Sites, the global trade organization dedicated to representing the interests of clinical research sites, today announced new developments to its landmark Site Advocacy Group initiative. The Site Advocacy Group (SAG) initiative enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools, and technologies.
Since its inception in early 2014, the SAG initiative has exercised considerable impact on the clinical research landscape by inciting important dialogue between site professionals and industry leaders related to current and evolving practices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.